Status:

COMPLETED

AXIOS CHINA (E7148)

Lead Sponsor:

Boston Scientific Corporation

Conditions:

Pancreatic Pseudocyst and Walled-off Necrosis

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

To study the safety and effectiveness of the AXIOS Stent with Electrocautery Enhanced Delivery System for endoscopic trans enteric drainage of pancreatic pseudocyst and walled-off necrosis in Chinese ...

Eligibility Criteria

Inclusion

  • Age between 18 and 75 years old(including 18 and 75 years old)
  • Eligible for endoscopic intervention
  • Acceptable candidate for endoscopic transluminal pancreatic pseudocyst drainage
  • Diagnostic as symptomatic pancreatic pseudocysts ≥ 6cm in maximum diameter and walled-off necrosis ≥ 6cm in maximum diameter with ≥ 70% fluid content that are adherent to the gastric or bowel wall
  • Patient understands the study requirements and the treatment procedures and provides written Informed Consent.
  • Patient is willing to comply with all specified follow-up evaluations, including willingness to undergo a pre/post CT imaging study.

Exclusion

  • \<18 or \>75 years of age
  • pseudocysts or walled-off necrosis which require nasocystic drainage,or\<6cm in maximum diameter, or walled-off necrosis \< 70% fluid content
  • The fluid collection to be drained is an immature pseudocyst
  • The fluid collection to be drained is a cystic neoplasm
  • The fluid collection to be drained is a pseudoaneurysm
  • The fluid collection to be drained is a duplication cyst
  • The fluid collection to be drained is a non-inflammatory fluid collection
  • There is more than one pseudocyst requiring drainage
  • Abnormal coagulation: INR \> 1.5 and not correctable presence of a bleeding disorder; platelets \< 50,000/mm3
  • Altered anatomy that precludes the physician's ability to deliver the stent (decision on a case by case basis).
  • Intervening gastric varices or vessels within a one centimeter radius of the needle (visible using endoscopy or endoscopic ultrasound)
  • Any prior true anaphylactic reaction to contrast agents, nitinol (nickel titanium), silicone or any other materials contacting the patient.
  • Female of childbearing potential with a positive pregnancy test prior to the procedure or intends to become pregnant during the study.
  • Currently participating in another investigational drug of device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.

Key Trial Info

Start Date :

April 17 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 30 2021

Estimated Enrollment :

31 Patients enrolled

Trial Details

Trial ID

NCT03808272

Start Date

April 17 2019

End Date

October 30 2021

Last Update

November 15 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100000